sector medic suppli devic
messag deliv mix perform revenu mere match
consensu lower expect tax rate drove ep beat
said organ sale growth still came strong despit tough yoy comp
manag rais low end guidanc top bottom
line given compani current momentum see high end rang
achiev posit one best fundament stori
sector rais pt reiter
buy rate
instrument real star mix quarter top line first quarter
revenu line consensu rose underli basi
mark eleventh straight quarter top line gain overal sale
result solid individu compon mix medsurg post revenu
organ top consensu offset miss ortho
neurotech spine busi unit level standout quarter
instrument balanc miss trauma extrem
medic neurotech spine top line ep
came ahead consensu line item ad howev
ebita margin contract face dilut recent
headwind despit slow start year profit perspect
cfo glenn boehnlein express confid compani full year guidanc
ebita leverag meanwhil manag took low end outlook
organ revenu growth vs previous high end rang
much play view combin continu see anoth year solid
double-digit earn growth
turn back quarter mako continu demonstr strong momentum
placement line think yoy overal
robot procedur volum mako tka case flat sequenti
given natur season ortho market howev view
solid result estim domest knee case perform
robot year ago see figur meanwhil note order
backlog new system remain robust suggest slowdown demand despit
recent fda approv rosa robot system
meanwhil rest ortho busi turn somewhat disappoint
total orthoped sale rose cc came consensu
trauma extrem account bulk miss delay launch
new alpha nail system caus sale cc come light
street forecast full launch expect around mid-year elsewher knee sale
cc miss consensu hip revenu cc
in-lin street
meanwhil instrument led way medsurg turn strong quarter
report medsurg sale organ upsid instrument
drove major beat sale organ top consensu
medic revenu organ came street expect
meanwhil endoscopi sale organ top consensu
recent launch new camera endoscopi segment pois
improv momentum move final sustain divis
post revenu ahead street
continu page
page analyst certif import disclosur
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
elsewher neurotech spine disappoint total neurotech spine sale
grew organ basi short consensu spine sale
miss street expect pro forma basi
integr still on-going manag indic process track in-lin
expect thu far express confid combin busi deliv
mid-single-digit pro forma growth overal meanwhil although estim
neuro organ growth acceler sequenti revenu
still miss aggress consensu forecast
top line lower expect interest/oth tax boost earn
stryker gross margin contract yoy came
consensu price pressur busi mix off-set tailwind
sg spend increas yoy sale consensu
meanwhil spend grew yoy sale lower
street model collect result ebita margin yoy
street estim lower expect tax rate interest/oth
expens ad earn math howev also import point
currenc headwind quarter vs impact compani
expect start
mix bag confid sustain growth
unchang model call ep sale
organ compar previou estim
respect long-term believ right mix end market
differenti product expertis sustain top line growth trajectori
next year combin improv execut margin
set compani one best fundament stori large-cap med-tech
view share trade today modest premium group ntm
ep vs think underst differenti natur busi rel
peer rais price target base
multipl previous revis forward ntm ep estim
signific upsid potenti target current level reiter buy rate
page analyst certif import disclosur
believ diversifi busi model posit sustain revenu growth
high end large-cap group compani seven differ busi
contribut overal revenu one franchis respons
uniqu model insul temporari weak one
segment view allow cast wide net potenti valu creat
acquisit result one consist top line growth stori large-
cap med-tech past year expect continu go forward drive
sustain ep growth potenti faster gain execut around
margin leverag improv deploy balanc sheet capac net
debt/ebitda today product manner believ profil warrant premium
valuat rel peer
share current trade ntm ep estim ntm
ebitda premium large-cap med-tech averag ntm ep
ntm ebitda believ superior growth profil peg
top bottom line vs group averag warrant
premium valuat increas price target previous
base multipl previous revis forward ntm ep estim
signific upsid potenti target current level assign stryker buy
downsid risk rate price target includ slowdown mako adopt
competit robot surgeri system roll increas price and/or volum pressur
ortho implant manufactur govern initi contain healthcar cost
weak hospit capit equip spend could neg impact
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
